Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein

Autor:	John J.V. McMurray, Jean-Claude Tardif, Stephen J. Nicholls, Christie M. Ballantyne, David Kallend, Eran Leitersdorf, Gregory G. Schwartz, Elise Gunzburger, Reynaria Pitts, Lawrence A. Leiter, Anders G. Olsson, Eric J. Niesor, John Kittelson, Prediman K. Shah, Philip J. Barter
Rok vydání:	2016
Předmět:	Male medicine.medical_specialty Dalcetrapib Coronary Disease 030204 cardiovascular system & hematology law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine High-density lipoprotein Randomized controlled trial law Internal medicine Outcome Assessment Health Care Epidemiology medicine Humans Sulfhydryl Compounds 030212 general & internal medicine Lipoprotein cholesterol biology business.industry Cholesterol Anticholesteremic Agents Cholesterol HDL C-reactive protein Healthy subjects Esters Middle Aged Amides Cholesterol Ester Transfer Proteins C-Reactive Protein Endocrinology chemistry biology.protein Female lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business
Zdroj:	Journal of the American College of Cardiology. 68:2488-2490
ISSN:	0735-1097
DOI:	10.1016/j.jacc.2016.09.932
Popis:	Epidemiological data associate higher concentrations of high-density lipoprotein cholesterol (HDL-C) with lower cardiovascular risk. HDL-C isolated from healthy subjects exhibits potentially protective properties, including anti-inflammatory effects [(1)][1]. However, some evidence suggests that
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d36b7c8dfde746b484de29671b750fd https://doi.org/10.1016/j.jacc.2016.09.932 Zobrazit plný text záznamu